Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19590385 | 0.92 | FGFR1 (0.35) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL19993637 | 0.90 | FGFR1 (0.36) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL19590320 | 0.89 | FGFR1 (0.33) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL20629113 | 0.89 | FGFR1 (0.33) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL20194616 | 0.89 | FGFR1 (0.33) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL20724461 | 0.88 | FGFR1 (0.33) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL18879992 | 0.88 | FGFR1 (0.33) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL18672197 | 0.88 | FGFR1 (0.33) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL22364090 | 0.87 | FGFR1 (0.32) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 | |
| SCHEMBL18877616 | 0.87 | FGFR1 (0.32) | FGFR1SLC22A6PDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190054108-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2019-02-21 | — | — | US | disclosed |
| US-9603863-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054108-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | FGFR1 1766/4885SLC22A6 861/4885PDE4D 216/4885 |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | FGFR1 1766/4885SLC22A6 861/4885PDE4D 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.